Harm van Tinteren
- Surgery top 0.2%
- Pulmonary and Respiratory Medicine top 0.2%
- Oncology top 0.2%
- Molecular Biology top 2%
- Emergency Medicine top 0.1%
- Co-authors
- Victor J. VerwaalHenk BootF.A.N. ZoetmulderSerge van RuthSimon HorenblasGooike W. van SlootenEelco de BreeEgbert F. Smit
- Topics
- Renal and related cancers (53 papers)Lung Cancer Treatments and Mutations (39 papers)Renal cell carcinoma treatment (37 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Harm van Tinteren
336 papers receiving 16.6k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Surgery 6.1k
- Pulmonary and Respiratory Medicine 5.7k
- Oncology 5.2k
- Molecular Biology 3.0k
- Emergency Medicine 2.1k
Countries citing papers authored by Harm van Tinteren
This map shows the geographic impact of Harm van Tinteren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm van Tinteren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm van Tinteren more than expected).
Fields of papers citing papers by Harm van Tinteren
This network shows the impact of papers produced by Harm van Tinteren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm van Tinteren. The network helps show where Harm van Tinteren may publish in the future.
Co-authorship network of co-authors of Harm van Tinteren
This figure shows the co-authorship network connecting the top 25 collaborators of Harm van Tinteren. A scholar is included among the top collaborators of Harm van Tinteren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harm van Tinteren. Harm van Tinteren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 8 | |
| 5 | 4 | |
| 6 | 13 | |
| 7 | 34 | |
| 8 | First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis | 4 |
| 9 | 21 | |
| 10 | 17 | |
| 11 | 7 | |
| 12 | TREATMENT OF RELAPSED WILMS TUMOUR (WT) PATIENTS: EXPERIENCE WITH TOPOTECAN | 3 |
| 13 | 68 | |
| 14 | 61 | |
| 15 | 54 | |
| 16 | 1 | |
| 17 | 4 | |
| 18 | SIGNIFICANCE OF LYMPH NODE INVOLVEMENT IN NEPHROBLASTOMA | 4 |
| 19 | 12 | |
| 20 | 108 |
About Harm van Tinteren
Harm van Tinteren is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology, having authored 340 papers that have together received 17.1k indexed citations. Recurring topics across this work include Renal and related cancers (53 papers), Lung Cancer Treatments and Mutations (39 papers) and Renal cell carcinoma treatment (37 papers). The work is most often cited by research in Reproductive Medicine (1.9k citations), Emergency Medicine (2.1k citations) and Oncology (5.2k citations). Harm van Tinteren has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Victor J. Verwaal, Henk Boot, F.A.N. Zoetmulder, Serge van Ruth, Simon Horenblas, Gooike W. van Slooten, Eelco de Bree, Egbert F. Smit, Otto S. Hoekstra and Sjoerd C. Bruin. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.